[go: up one dir, main page]

WO2006128129A3 - Method for treating cancer - Google Patents

Method for treating cancer Download PDF

Info

Publication number
WO2006128129A3
WO2006128129A3 PCT/US2006/020821 US2006020821W WO2006128129A3 WO 2006128129 A3 WO2006128129 A3 WO 2006128129A3 US 2006020821 W US2006020821 W US 2006020821W WO 2006128129 A3 WO2006128129 A3 WO 2006128129A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating cancer
rel
modulate
activity
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/020821
Other languages
French (fr)
Other versions
WO2006128129A2 (en
Inventor
John Bertin
Ethan P Grant
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synta Phamaceuticals Corp
Original Assignee
Synta Phamaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synta Phamaceuticals Corp filed Critical Synta Phamaceuticals Corp
Publication of WO2006128129A2 publication Critical patent/WO2006128129A2/en
Anticipated expiration legal-status Critical
Publication of WO2006128129A3 publication Critical patent/WO2006128129A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to a method for treating cancers using compounds that modulate the activity of c-Rel.
PCT/US2006/020821 2005-05-26 2006-05-26 Method for treating cancer Ceased WO2006128129A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68505605P 2005-05-26 2005-05-26
US60/685,056 2005-05-26
US72035705P 2005-09-23 2005-09-23
US60/720,357 2005-09-23

Publications (2)

Publication Number Publication Date
WO2006128129A2 WO2006128129A2 (en) 2006-11-30
WO2006128129A3 true WO2006128129A3 (en) 2008-10-30

Family

ID=37452974

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/020821 Ceased WO2006128129A2 (en) 2005-05-26 2006-05-26 Method for treating cancer

Country Status (1)

Country Link
WO (1) WO2006128129A2 (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8372971B2 (en) 2004-08-25 2013-02-12 Targegen, Inc. Heterocyclic compounds and methods of use
US8481536B2 (en) 2004-04-08 2013-07-09 Targegen, Inc. Benzotriazine inhibitors of kinases
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US8754092B2 (en) 2007-03-14 2014-06-17 Exelixis Patent Company Llc Inhibitors of the hedgehog pathway
US8987272B2 (en) 2010-04-01 2015-03-24 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
US9284275B2 (en) 2007-01-11 2016-03-15 Critical Outcome Technologies Inc. Inhibitor compounds and cancer treatment methods
US10179135B2 (en) 2014-01-24 2019-01-15 Lam Therapeutics, Inc. Apilimod compositions and methods for using same
US10350213B2 (en) 2015-07-20 2019-07-16 AI Therapeutics, Inc. Methods for treating cancer using apilimod
US10729694B2 (en) 2015-01-23 2020-08-04 AI Therapeutics, Inc. Anti-viral compositions containing PIKfyve inhibitors and use thereof
US10751345B2 (en) 2018-02-21 2020-08-25 AI Therapeutics, Inc. Combination therapy with apilimod and glutamatergic agents
US10765682B2 (en) 2014-11-07 2020-09-08 AI Therapeutics, Inc. Apilimod for use in the treatment of melanoma
US11168068B2 (en) 2016-07-18 2021-11-09 Janssen Pharmaceutica Nv Tau PET imaging ligands
US11166944B2 (en) 2014-11-07 2021-11-09 AI Therapeutics, Inc. Apilimod compositions and methods for using same in the treatment of renal cancer

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10323345A1 (en) 2003-05-23 2004-12-16 Zentaris Gmbh New pyridopyrazines and their use as kinase inhibitors
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
PL1951684T3 (en) 2005-11-01 2017-03-31 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
EP1790342A1 (en) 2005-11-11 2007-05-30 Zentaris GmbH Pyridopyrazine derivatives and their use as signal transduction modulators
ES2555803T3 (en) 2006-10-23 2016-01-08 Cephalon, Inc. Fusion of bicyclic 2,4-diaminopyrimidine derivatives as using ALK and c-Met inhibitors
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
TWI475996B (en) 2007-10-19 2015-03-11 Celgene Avilomics Res Inc Heteroaryl compounds and uses thereof
WO2009079797A1 (en) 2007-12-26 2009-07-02 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
WO2009089277A2 (en) * 2008-01-08 2009-07-16 The Trustees Of The University Of Pennsylvania Rel inhibitors and methods of use thereof
KR101608096B1 (en) 2008-01-23 2016-03-31 브리스톨-마이어스 스큅 컴퍼니 4-pyridinone compounds and their use for cancer
US20110098267A1 (en) * 2008-02-07 2011-04-28 Synta Pharmaceuticals Corporation Topical formulations for the treatment of psoriasis
BRPI0908637B8 (en) 2008-05-21 2021-05-25 Ariad Pharma Inc compound and pharmaceutical composition thereof
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
RU2536584C2 (en) 2008-06-27 2014-12-27 Авила Терапьютикс, Инк. Heteroaryl compounds and using them
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
EP2440559B1 (en) 2009-05-05 2018-01-10 Dana-Farber Cancer Institute, Inc. Egfr inhibitors and methods of treating disorders
CA2803687C (en) 2010-07-20 2019-04-30 Vestaron Corporation Insecticidal triazines and pyrimidines
AU2011289604C1 (en) 2010-08-10 2016-04-21 Celgene Avilomics Research, Inc. Besylate salt of a BTK inhibitor
MX2013003913A (en) 2010-10-08 2013-09-26 Abbvie Inc FURO[3,2-d]PYRIMIDINE COMPOUNDS.
TWI545115B (en) 2010-11-01 2016-08-11 阿維拉製藥公司 Heterocyclic compounds and uses thereof
EP2635285B1 (en) 2010-11-01 2017-05-03 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
AU2010363329A1 (en) 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
JP5957003B2 (en) 2010-11-10 2016-07-27 セルジーン アヴィロミクス リサーチ， インコーポレイテッド Mutant selective EGFR inhibitor and use thereof
PL2670753T3 (en) 2011-01-31 2017-05-31 Novartis Ag Novel heterocyclic derivatives
AU2012250517B2 (en) 2011-05-04 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
TW201325593A (en) 2011-10-28 2013-07-01 Celgene Avilomics Res Inc Methods of treating a BRUTON'S tyrosine kinase disease or disorder
CA2853256C (en) 2011-10-28 2019-05-14 Novartis Ag Novel purine derivatives and their use in the treatment of disease
EA026368B1 (en) 2011-12-21 2017-03-31 Новира Терапьютикс, Инк. Hepatitis b antiviral agents
MX356753B (en) 2012-03-15 2018-06-12 Celgene Avilomics Res Inc Solid forms of an epidermal growth factor receptor kinase inhibitor.
PL2825042T3 (en) 2012-03-15 2019-02-28 Celgene Car Llc Salts of an epidermal growth factor receptor kinase inhibitor
JPWO2013146963A1 (en) 2012-03-28 2015-12-14 武田薬品工業株式会社 Heterocyclic compounds
WO2013152717A1 (en) * 2012-04-10 2013-10-17 上海昀怡健康管理咨询有限公司 Fused pyrimidine compound, and preparation method, intermediate, composition， and uses thereof
WO2013169401A1 (en) 2012-05-05 2013-11-14 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
SG11201501359TA (en) 2012-08-28 2015-03-30 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
EP2935226A4 (en) 2012-12-21 2016-11-02 Celgene Avilomics Res Inc Heteroaryl compounds and uses thereof
CA2900012A1 (en) 2013-02-08 2014-08-14 Celgene Avilomics Research, Inc. Erk inhibitors and uses thereof
CA2899706C (en) 2013-02-28 2021-10-19 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
US8993771B2 (en) 2013-03-12 2015-03-31 Novira Therapeutics, Inc. Hepatitis B antiviral agents
US9834520B2 (en) 2013-03-14 2017-12-05 Takeda Pharmaceutical Company Limited Heterocyclic compound
HUE033542T2 (en) 2013-04-03 2017-12-28 Janssen Sciences Ireland Uc N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
JO3603B1 (en) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc Sulfamoyl pyrolamide derivatives and their use as medicines to treat hepatitis B
JP6411342B2 (en) 2013-07-03 2018-10-24 武田薬品工業株式会社 Amide compounds
WO2015002231A1 (en) 2013-07-03 2015-01-08 武田薬品工業株式会社 Heterocyclic compound
DK3024819T3 (en) 2013-07-25 2018-06-06 Janssen Sciences Ireland Uc GLYOXAMIDE-SUBSTITUTED PYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICINES FOR TREATING HEPATITIS B
WO2015016206A1 (en) 2013-07-30 2015-02-05 武田薬品工業株式会社 Heterocyclic compound
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
AU2014338947B2 (en) 2013-10-23 2018-02-22 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
KR20160128305A (en) 2014-02-05 2016-11-07 노비라 테라퓨틱스, 인코포레이티드 Combination therapy for treatment of hbv infections
PL3102572T3 (en) 2014-02-06 2019-04-30 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
US9400280B2 (en) 2014-03-27 2016-07-26 Novira Therapeutics, Inc. Piperidine derivatives and methods of treating hepatitis B infections
US10005760B2 (en) 2014-08-13 2018-06-26 Celgene Car Llc Forms and compositions of an ERK inhibitor
KR102431436B1 (en) 2014-08-29 2022-08-10 테스 파마 에스.알.엘. INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE
CN106146361A (en) * 2015-03-16 2016-11-23 四川大学 Indenes-1-subunit sulfonyl benzoyl hydrazine derivant and its production and use
CN107847762A (en) 2015-03-19 2018-03-27 诺维拉治疗公司 Azacyclooctane and azacyclononane derivatives and methods of treating hepatitis B infection
WO2016160102A1 (en) 2015-03-31 2016-10-06 Lam Therapeutics, Inc. Active metabolites of apilimod and uses thereof
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
RS62639B1 (en) 2015-07-06 2021-12-31 Alkermes Inc Hetero-halo inhibitors of histone deacetylase
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
CN105130907B (en) * 2015-07-29 2018-10-16 沈阳药科大学 Pyrimidines and application thereof
WO2017059059A1 (en) 2015-09-29 2017-04-06 Novira Therapeutics, Inc. Crystalline forms of a hepatitis b antiviral agent
CR20180323A (en) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd DERIVATIVES OF INDOL N-SUBSTITUTES AS MODULATORS OF PGE2 RECEIVERS
RU2018130070A (en) * 2016-01-21 2020-02-21 Лэм Терапьютикс, Инк. BIOMARKERS FOR TREATING CANCER USING APILIMODA
SG10202011827YA (en) 2016-04-15 2021-01-28 Novira Therapeutics Inc Combinations and methods comprising a capsid assembly inhibitor
EP3503925A1 (en) 2016-08-25 2019-07-03 AI Therapeutics, Inc. Compositions comprising pikfyve inhibitors and methods related to inhibition of rank signaling
EP3525794A1 (en) 2016-10-12 2019-08-21 AI Therapeutics, Inc. Apilimod compositions and methods for using same in the treatment of alzheimer's disease
TWI770104B (en) 2017-01-11 2022-07-11 美商羅登醫療公司 Bicyclic inhibitors of histone deacetylase
US10702534B2 (en) 2017-03-31 2020-07-07 AI Therapeutics, Inc. Compositions and methods relating to the radioprotective effects of apilimod
WO2018210987A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Benzofurane and benzothiophene derivatives as pge2 receptor modulators
CA3060394A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives as pge2 receptor modulators
CA3063788A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives
HRP20211532T1 (en) 2017-05-18 2022-01-07 Idorsia Pharmaceuticals Ltd N-substituted indole derivatives
EA201992676A1 (en) 2017-05-18 2020-05-06 Идорсия Фармасьютиклз Лтд PHENIL DERIVATIVES AS PGE2 RECEPTOR MODULATORS
PL3664802T3 (en) 2017-08-07 2022-07-11 Alkermes, Inc. Bicyclic inhibitors of histone deacetylase
EP3676264A1 (en) 2017-08-28 2020-07-08 Acurastem Inc. Pikfyve kinase inhibitors
EP3765011A1 (en) 2018-03-14 2021-01-20 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen
KR20210029790A (en) 2018-07-05 2021-03-16 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 PIKfyve inhibitor
US12415816B2 (en) 2018-11-07 2025-09-16 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
KR20210130753A (en) 2019-02-22 2021-11-01 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 Amide derivatives useful for the treatment of HBV infection or HBV-induced disease
EP3966205A1 (en) 2019-05-06 2022-03-16 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of hbv infection or hbv-induced diseases
FI3966206T3 (en) 2019-05-10 2023-10-20 Deciphera Pharmaceuticals Llc Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
MX2021013661A (en) 2019-05-10 2022-03-11 Deciphera Pharmaceuticals Llc PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE OF THESE.
PH12021553166A1 (en) 2019-06-17 2022-08-15 Deciphera Pharmaceuticals Llc Aminopyrimidine amide autophagy inhibitors and methods of use thereof
JP2022539208A (en) 2019-07-03 2022-09-07 スミトモ ファーマ オンコロジー， インコーポレイテッド Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
AR119934A1 (en) 2019-09-12 2022-01-19 Ai Therapeutics Inc PIKFYVE INHIBITORS FOR CANCER THERAPY
CA3170133A1 (en) 2020-02-07 2021-08-12 AI Therapeutics, Inc. Anti-viral compositions and methods of use
WO2021163727A1 (en) 2020-02-11 2021-08-19 AcuraStem Incorporated Pikfyve kinase inhibitors
TW202208355A (en) 2020-05-04 2022-03-01 美商安進公司 Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
JP7741100B2 (en) 2020-05-04 2025-09-17 アムジェン インコーポレイテッド Heterocyclic compounds as trigger receptor 2 agonists expressed on myeloid cells and methods of use
EP4146639A1 (en) 2020-05-06 2023-03-15 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
WO2022067462A1 (en) * 2020-09-29 2022-04-07 Beigene (Beijing) Co., Ltd. Process for preparing inhibitors of kras g12c
EP4225742A4 (en) 2020-10-05 2024-11-06 Enliven Inc. 5- and 6-azaindole compounds for inhibition of bcr-abl tyrosine kinases
EP4267574B1 (en) 2020-12-23 2025-04-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
JP2024521449A (en) 2021-06-11 2024-05-31 オルフアイ セラピューティクス インコーポレイテッド Stabilized apilimod compositions and methods of use thereof
EP4430042A1 (en) 2021-11-09 2024-09-18 Ajax Therapeutics, Inc. 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
TW202325289A (en) 2021-11-09 2023-07-01 美商雅捷可斯治療公司 Forms and compositions of inhibitors of jak2
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
US20250282767A1 (en) 2022-05-02 2025-09-11 AcuraStem Incorporated Pikfyve kinase inhibitors
WO2025229177A1 (en) 2024-05-02 2025-11-06 Idorsia Pharmaceuticals Ltd Crystalline forms of an n-substituted indole derivative
CN119746105B (en) * 2024-12-31 2025-07-11 中国医学科学院基础医学研究所 Application of CD40 antibody and LPS co-stimulated genetically modified B cells in treatment of cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003022274A2 (en) * 2001-09-13 2003-03-20 Synta Pharmaceuticals Corp. 2-aroylimidazole compounds for treating cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003022274A2 (en) * 2001-09-13 2003-03-20 Synta Pharmaceuticals Corp. 2-aroylimidazole compounds for treating cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHEHATA M. ET AL.: "Dual Apoptotic Effect of Xrel3-c-Rel/NF-kappaB Homolog in Human Cervical Cancer Cells", CELL BIOLOGY INTERNATIONAL, vol. 28, no. 12, 2004, pages 895 - 904, XP004654766 *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8481536B2 (en) 2004-04-08 2013-07-09 Targegen, Inc. Benzotriazine inhibitors of kinases
US8372971B2 (en) 2004-08-25 2013-02-12 Targegen, Inc. Heterocyclic compounds and methods of use
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US9284275B2 (en) 2007-01-11 2016-03-15 Critical Outcome Technologies Inc. Inhibitor compounds and cancer treatment methods
US8754092B2 (en) 2007-03-14 2014-06-17 Exelixis Patent Company Llc Inhibitors of the hedgehog pathway
US8796294B2 (en) 2007-03-14 2014-08-05 Exelixis Patent Company Llc Inhibitors of the hedgehog pathway
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
US8987272B2 (en) 2010-04-01 2015-03-24 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV
US9422282B2 (en) 2010-04-01 2016-08-23 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV
US10179135B2 (en) 2014-01-24 2019-01-15 Lam Therapeutics, Inc. Apilimod compositions and methods for using same
US11266654B2 (en) 2014-01-24 2022-03-08 AI Therapeutics, Inc. Apilimod compositions and methods for using same
US11166944B2 (en) 2014-11-07 2021-11-09 AI Therapeutics, Inc. Apilimod compositions and methods for using same in the treatment of renal cancer
US10765682B2 (en) 2014-11-07 2020-09-08 AI Therapeutics, Inc. Apilimod for use in the treatment of melanoma
US10729694B2 (en) 2015-01-23 2020-08-04 AI Therapeutics, Inc. Anti-viral compositions containing PIKfyve inhibitors and use thereof
US10350213B2 (en) 2015-07-20 2019-07-16 AI Therapeutics, Inc. Methods for treating cancer using apilimod
US11168068B2 (en) 2016-07-18 2021-11-09 Janssen Pharmaceutica Nv Tau PET imaging ligands
US12006302B2 (en) 2016-07-18 2024-06-11 Janssen Pharmaceutica Nv Tau PET imaging ligands
US10751345B2 (en) 2018-02-21 2020-08-25 AI Therapeutics, Inc. Combination therapy with apilimod and glutamatergic agents
US11439649B2 (en) 2018-02-21 2022-09-13 AI Therapeutics, Inc. Combination therapy with apilimod and glutamatergic agents
US11957688B2 (en) 2018-02-21 2024-04-16 OrphAl Therapeutics Inc. Combination therapy with apilimod and glutamatergic agents

Also Published As

Publication number Publication date
WO2006128129A2 (en) 2006-11-30

Similar Documents

Publication Publication Date Title
WO2006128129A3 (en) Method for treating cancer
ZA200805877B (en) Pyridiazinone derivatives for tumour treatment
IL197914A (en) Anti-ereg antibodies for treating cancer
ZA200805760B (en) Method for treating disseminated cancer
AU2007288337A8 (en) Compounds for treating proliferative disorders
ZA200709620B (en) Methods for treating drug resistant cancer
IL178920A0 (en) Treatment for pancreatic cancer
PT1830847E (en) Treatment for cancer
EP1909854A4 (en) Method for treating cancer
IL189377A0 (en) Combinations comprising dmxaa for the treatment of cancer
GB2435169B (en) Process for treating an underground formation
IL181332A0 (en) Prostaglandin derivatives for treating gastrointestinal disorder
SI1846022T1 (en) Methods for treating adhesive capsulitis
GB0803521D0 (en) A pharmaceutcal composition useful for the treatment of prostate cancer
IL226362A0 (en) Compounds, and methods for the treatment of cancer
ZA200805522B (en) Dioxoiane dérivates for the treatment of cancer
EP1956135A4 (en) Apparatus for treating papermaking feedstock
GB0508622D0 (en) Method for treating effluent
AU2005903890A0 (en) Method for treating cancer
ZA200702625B (en) Prostaglandin derivatives for treating gastrointestinal disorder
AU2007906570A0 (en) Compounds for treating cancer
GB0517386D0 (en) Combinations for the treatment of cancer
HK1102261A (en) Method of treating brain cancer
HU0500612D0 (en) Treating apparatus for preventing cancer
HK1115317A (en) Combinations comprising dmxaa for the treatment of cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06771527

Country of ref document: EP

Kind code of ref document: A2